Cargando…
Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations
Chronic stable angina pectoris is the primary indication for ranolazine (RZ), an anti-anginal drug. The drug has an anti-ischemic action that is unaffected by either blood pressure or heart rate. Due to the first-pass effect, the drug has a reduced bioavailability of 35 to 50%. The study emphasized...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458271/ https://www.ncbi.nlm.nih.gov/pubmed/37631066 http://dx.doi.org/10.3390/ph16081151 |
_version_ | 1785097127385366528 |
---|---|
author | Unnisa, Aziz Chettupalli, Ananda K. Alazragi, Reem S. Alelwani, Walla Bannunah, Azzah M. Barnawi, Jameel Amarachinta, Padmanabha R. Jandrajupalli, Suresh B. Elamine, Badria A. Mohamed, Omkalthoum A. Hussain, Talib |
author_facet | Unnisa, Aziz Chettupalli, Ananda K. Alazragi, Reem S. Alelwani, Walla Bannunah, Azzah M. Barnawi, Jameel Amarachinta, Padmanabha R. Jandrajupalli, Suresh B. Elamine, Badria A. Mohamed, Omkalthoum A. Hussain, Talib |
author_sort | Unnisa, Aziz |
collection | PubMed |
description | Chronic stable angina pectoris is the primary indication for ranolazine (RZ), an anti-anginal drug. The drug has an anti-ischemic action that is unaffected by either blood pressure or heart rate. Due to the first-pass effect, the drug has a reduced bioavailability of 35 to 50%. The study emphasized developing a novel transdermal drug delivery system of nanostructured lipid carriers (NLCs) for delivering RZ. Many pharmaceutical companies employ lipid nanoparticles as biocompatible carriers for medicinal, cosmetic, and biochemical uses. These carriers are appropriate for many applications, such as topical, transdermal, parenteral, pulmonary, and oral administration, because of the large variety of lipids and surfactants that are readily available for manufacturing. RZ NLCs were made using high-pressure homogenization. Statistical analysis was utilized to find the best formula by varying the concentrations of Precirol ATO 5 (X1), oleic acid (X2), and Tween 80 (X3). Variables such as entrapment effectiveness (EE) (Y1), particle size (Y2), polydispersity index (PDI) (Y3), and zeta potential (Y4) were tested. A variety of tests were performed on the new formulation to ascertain how well it would be absorbed in the body. These tests included in vivo absorption studies, skin permeability assessments, in vitro drug release assessments, and physicochemical analyses. The particle size of RZ-NLCs was shown to be very small (118.4 ± 5.94 nm), with improved EE (88.39 ± 3.1%) and low ZP and PDI (−41.91 ± 0.38 and 0.118 ± 0.028). SEM and TEM analysis confirmed the structure of the NLCs and showed a smooth, spherical surface. Improved RZ-NLCs were used to create NLC gel, which was then tested for elasticity both physically and rheologically. The formulation’s elasticity was investigated. Optimized RZ-NLCs and NLCG were found to have transdermal fluxes of 48.369 g/cm(2)/h and 38.383 g/cm(2)/h, respectively. These results showed that the transdermal delivery of RZ distribution through NLC’s transdermal gel had more significant potential. According to in vivo experiments, the drug’s bioavailability in Wistar rats increased when it was delivered through NLCs. The findings demonstrated that NLCs loaded with RZ successfully transported the RZ to the designated site with no interruptions and that a quadratic connection existed between the independent and dependent variables. |
format | Online Article Text |
id | pubmed-10458271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104582712023-08-27 Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations Unnisa, Aziz Chettupalli, Ananda K. Alazragi, Reem S. Alelwani, Walla Bannunah, Azzah M. Barnawi, Jameel Amarachinta, Padmanabha R. Jandrajupalli, Suresh B. Elamine, Badria A. Mohamed, Omkalthoum A. Hussain, Talib Pharmaceuticals (Basel) Article Chronic stable angina pectoris is the primary indication for ranolazine (RZ), an anti-anginal drug. The drug has an anti-ischemic action that is unaffected by either blood pressure or heart rate. Due to the first-pass effect, the drug has a reduced bioavailability of 35 to 50%. The study emphasized developing a novel transdermal drug delivery system of nanostructured lipid carriers (NLCs) for delivering RZ. Many pharmaceutical companies employ lipid nanoparticles as biocompatible carriers for medicinal, cosmetic, and biochemical uses. These carriers are appropriate for many applications, such as topical, transdermal, parenteral, pulmonary, and oral administration, because of the large variety of lipids and surfactants that are readily available for manufacturing. RZ NLCs were made using high-pressure homogenization. Statistical analysis was utilized to find the best formula by varying the concentrations of Precirol ATO 5 (X1), oleic acid (X2), and Tween 80 (X3). Variables such as entrapment effectiveness (EE) (Y1), particle size (Y2), polydispersity index (PDI) (Y3), and zeta potential (Y4) were tested. A variety of tests were performed on the new formulation to ascertain how well it would be absorbed in the body. These tests included in vivo absorption studies, skin permeability assessments, in vitro drug release assessments, and physicochemical analyses. The particle size of RZ-NLCs was shown to be very small (118.4 ± 5.94 nm), with improved EE (88.39 ± 3.1%) and low ZP and PDI (−41.91 ± 0.38 and 0.118 ± 0.028). SEM and TEM analysis confirmed the structure of the NLCs and showed a smooth, spherical surface. Improved RZ-NLCs were used to create NLC gel, which was then tested for elasticity both physically and rheologically. The formulation’s elasticity was investigated. Optimized RZ-NLCs and NLCG were found to have transdermal fluxes of 48.369 g/cm(2)/h and 38.383 g/cm(2)/h, respectively. These results showed that the transdermal delivery of RZ distribution through NLC’s transdermal gel had more significant potential. According to in vivo experiments, the drug’s bioavailability in Wistar rats increased when it was delivered through NLCs. The findings demonstrated that NLCs loaded with RZ successfully transported the RZ to the designated site with no interruptions and that a quadratic connection existed between the independent and dependent variables. MDPI 2023-08-14 /pmc/articles/PMC10458271/ /pubmed/37631066 http://dx.doi.org/10.3390/ph16081151 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Unnisa, Aziz Chettupalli, Ananda K. Alazragi, Reem S. Alelwani, Walla Bannunah, Azzah M. Barnawi, Jameel Amarachinta, Padmanabha R. Jandrajupalli, Suresh B. Elamine, Badria A. Mohamed, Omkalthoum A. Hussain, Talib Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations |
title | Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations |
title_full | Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations |
title_fullStr | Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations |
title_full_unstemmed | Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations |
title_short | Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations |
title_sort | nanostructured lipid carriers to enhance the bioavailability and solubility of ranolazine: statistical optimization and pharmacological evaluations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458271/ https://www.ncbi.nlm.nih.gov/pubmed/37631066 http://dx.doi.org/10.3390/ph16081151 |
work_keys_str_mv | AT unnisaaziz nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations AT chettupallianandak nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations AT alazragireems nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations AT alelwaniwalla nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations AT bannunahazzahm nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations AT barnawijameel nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations AT amarachintapadmanabhar nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations AT jandrajupallisureshb nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations AT elaminebadriaa nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations AT mohamedomkalthouma nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations AT hussaintalib nanostructuredlipidcarrierstoenhancethebioavailabilityandsolubilityofranolazinestatisticaloptimizationandpharmacologicalevaluations |